药捷安康-B(02617.HK)：替恩戈替尼片获国家药监局批准纳入优先审评品种名单

Core Viewpoint - The company药捷安康-B (02617.HK) has received approval from the National Medical Products Administration (NMPA) for its drug替恩戈替尼片 to be included in the priority review list for the treatment of advanced, metastatic, or unresectable cholangiocarcinoma in adult patients who have previously received at least one systemic therapy and FGFR inhibitor treatment [1] Group 1 - The drug替恩戈替尼片 is specifically indicated for adult patients with advanced, metastatic, or unresectable cholangiocarcinoma [1] - The NMPA has previously granted替恩戈替尼片 breakthrough therapy designation for the treatment of cholangiocarcinoma [1]